VERA (35) MRVI (36) AGIO (39) PVLA (46) ⌘ Pro Terminal →

Perrigo Company plc (PRGO) — RQD Stock Rating Cockpit

$15.90 -0.13% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Perrigo Company plc (PRGO) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.21B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRGO)Realized 20D OHLCV Swing Band: ±9%

RSI-14 MOMENTUMBULLISH MOMENTUM

55.330 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE58% OF RANGE

L: $9$15.90H: $21

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PRGO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-13.6% ROIC with 35.1% gross margin and 6.58% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 0.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

18/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like PRGO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRGO)

✓Walkthrough of PRGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.29%📐 HORIZONTAL RANGE

2026-10-30O $16.07H $16.14L $15.42C $15.90VOL 3.35M

RES: $17.25SUP: $8.73SMA50: $14.82SMA200: $12.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRGO Butterfly Map → + Track PRGO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRGO)

Health Care Rank #604 of 1016 ⚔️ VERA vs PRGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRGO vs. VERA, MRVI, AGIO, PVLA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Perrigo Company plc (PRGO) ranks #604 by composite RQD confidence (41/100, grade D-) and #242 by equity capitalization ($2.21B). Within this direct 5-issuer industry benchmark cohort, PRGO leads on earnings valuation at N/A trailing P/E, while PRGO leads on capital efficiency and profitability with -13.6% ROIC and 35.1% gross margin. PVLA currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with PRGO at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRGO ACTIVE Perrigo Company plc	D-	41/100	—	35.1%	-13.6%	-0.13%	$2.21B	Benchmark Subject
VERA Vera Therapeutics Inc. (Class A)	D-	35/100	—	—	-35.0%	-1.32%	$2.20B	/vera-vs-prgo →
MRVI Maravai LifeSciences Holdings Inc. (Class A)	D-	36/100	—	18.3%	-35.0%	-0.47%	$2.20B	/mrvi-vs-prgo →
AGIO Agios Pharmaceuticals Inc.	D-	39/100	—	88.3%	-33.8%	-2.33%	$2.22B	/agio-vs-prgo →
PVLA Palvella Therapeutics Inc.	D	46/100	—	—	-27.9%	+2.79%	$2.18B	/pvla-vs-prgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001585364

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Perrigo Company plc (PRGO) reported GAAP revenue of $4.25B (-2.8% vs. FY2024 revenue of $4.37B , and -8.6% cumulative change since FY2023) , GAAP net income of -$1.43B, operating cash flow of $238.5M, and free cash flow of $145.1M (-40.7% YoY). On the balance sheet, PRGO closed FY2025 with $8.54B in total assets against $3.60B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.25B	-$1.43B	$238.5M	$145.1M	$8.54B	$3.60B
FY2024 (FY)	2024-12-31	$4.37B	-$171.8M	$362.9M	$244.6M	$9.65B	$3.58B
FY2023 (FY)	2023-12-31	$4.66B	-$12.7M	$405.5M	$405.5M	—	—

3. PRGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Perrigo Company plc (NYSE: PRGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $15.90 (-0.13% 1D, market cap $2.21B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PRGO ranks #604 in composite RQD confidence.

How does PRGO compare to VERA and MRVI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRGO carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 35.1%, and ROIC of -13.6%. By comparison, VERA (Vera Therapeutics Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B) and MRVI (Maravai LifeSciences Holdings Inc. (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B). Among the 5-stock peer group, PRGO leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRGO?

Per PRGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585364), Perrigo Company plc generated $4.25B in revenue (-2.8% YoY), -$1.43B in net income, and $145.1M in free cash flow against $8.54B in total assets and $3.60B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRGO trading relative to its 50-day, 200-day, and 52-week technical levels?

PRGO last traded at $15.90 (-0.13% on volume of 2,288,844 shares), positioning the stock +7.29% above its 50-day simple moving average ($14.82) and +27.81% above its 200-day simple moving average ($12.44). Across its 52-week range of $9.23 to $20.65, PRGO sits at the 58.4% percentile with a 14-day RSI of 55.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.0% ($14.47 to $17.33).

PRGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PRGO stock right now?

Perrigo Company plc (PRGO) currently earns a Roarable Rating of D- (Sell — SELL) with 41/100 RQD Confidence. Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.

What is PRGO's 12-month price target and RQD AI Jury consensus?

PRGO's 12-month base price target is $14.68 (range $11.45 to $21.68), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PRGO RQD Cockpit PRGO 12M Forecast PRGO Earnings & Move PRGO Dividends & DRIP PRGO Insiders & 13F PRGO Whale Options PRGO Profit Sankey PRGO News & Why